https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-10-24 / J Extracell Vesicles 2013;2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-10-24 / J Extracell Vesicles 2013;22013-10-24 00:00:002019-02-15 08:46:15Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-10-21 / Neurol. Med. Chir. (Tokyo) 2013;53(11):741-54
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-10-21 / Neurol. Med. Chir. (Tokyo) 2013;53(11):741-542013-10-21 00:00:002019-02-15 08:47:29Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-10-04 / Expert Rev Vaccines 2013 Oct;12(10):1195-210
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-10-04 / Expert Rev Vaccines 2013 Oct;12(10):1195-2102013-10-04 00:00:002019-02-15 08:39:48Exploiting dendritic cells in the development of cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-10-01 / Immunotherapy 2013 Oct;5(10):1039-42
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-10-01 / Immunotherapy 2013 Oct;5(10):1039-422013-10-01 00:00:002019-02-15 08:50:41Vaccination with dendritic cell-tumor fusion cells in multiple myeloma patients: a promising strategy?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-10-01 / BioDrugs 2013 Oct;27(5):453-68
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-10-01 / BioDrugs 2013 Oct;27(5):453-682013-10-01 00:00:002019-02-15 08:39:51A review of dendritic cell therapy for cancer: progress and challenges
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-09-01 / Anticancer Res. 2013 Sep;33(9):3855-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-09-01 / Anticancer Res. 2013 Sep;33(9):3855-92013-09-01 00:00:002021-11-15 14:43:00Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-08-13 / Cryobiology 2013 Oct;67(2):235-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-08-13 / Cryobiology 2013 Oct;67(2):235-402013-08-13 00:00:002019-02-15 08:45:41Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-08-03 / Arch. Gynecol. Obstet. 2014 Jan;289(1):155-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-08-03 / Arch. Gynecol. Obstet. 2014 Jan;289(1):155-622013-08-03 00:00:002019-02-15 08:45:49In vitro and in vivo evaluations of human papillomavirus type 16 (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide (CpG-ODN) adjuvant as tumor vaccines for immunotherapy of cervical cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-08-01 / Breast 2013 Aug;22 Suppl 2:S96-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-08-01 / Breast 2013 Aug;22 Suppl 2:S96-92013-08-01 00:00:002019-02-15 08:50:01Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-08-01 / Scand. J. Immunol. 2013 Aug;78(2):167-71
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-08-01 / Scand. J. Immunol. 2013 Aug;78(2):167-712013-08-01 00:00:002019-02-15 08:39:49Current status and future perspectives of dendritic cell-based cancer immunotherapy
